Gene
CCND1
CCND1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (96), Actionable biomarkers (4), Trial mentions (67), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CCND1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 11 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 4 of 8,275 | 0.05% | 64 of 11,460 | 0.56% |
| 2022 | 4 of 8,285 | 0.05% | 80 of 13,598 | 0.59% |
| 2021 | 3 of 8,692 | 0.03% | 88 of 15,045 | 0.58% |
| 2020 | 5 of 7,640 | 0.07% | 77 of 14,459 | 0.53% |
| 2019 | 6 of 7,300 | 0.08% | 64 of 12,159 | 0.53% |
| 2018 | 6 of 6,927 | 0.09% | 76 of 11,854 | 0.64% |
| 2017 | 4 of 6,558 | 0.06% | 79 of 11,595 | 0.68% |
Showing 10 of 37 years.
Assay-provider ledger (96)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| University of Minnesota Genomics Center | Not a company | Clinical validationAnalytical validation | 1 | April 01, 2026 |
| CELL MARQUE | Reagent supplier | Clinical validation | 2 | April 01, 2025 |
| ROCHE | Context dependent | Clinical validationAnalytical validation | 2 | April 01, 2025 |
| VENTANA | Diagnostic provider | Clinical validation | 2 | April 01, 2025 +1 undated |
| Agilent Technologies | Reagent supplier | Clinical validationAnalytical validation | 5 | March 01, 2025 |
Showing 5 of 96 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CCND1 amplification | Cdk4/6 Inhibitors | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
| CCND1 amplification | Palbociclib | resistant | lung carcinoma | Cancer Genome Interpreter |
| CCND1 amplification | Smo Inhibitors | responsive | medulloblastoma | Cancer Genome Interpreter |
| CCND1 amplification | Cdk4/6 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (67)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04683757 | Trial biospecimen (AACT) |
| NCT02933736 | Trial eligibility (AACT) |
| NCT00816595 | Trial eligibility (AACT) |
| NCT03516617 | Trial eligibility (AACT) |
| NCT04557449 | Trial eligibility (AACT) |
Showing 5 of 67 trial mentions.
Target-disease associations (685)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| AL amyloidosis | cardiovascular disease | GWAS credible sets |
| Abnormality of refraction | phenotype | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
Showing 5 of 685 associations.
Vendor sourcing (193)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Abramson Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : \- Disease Characteristics: All Subjects: All subjects treated under this protocol will have histologically documented cancer of one of the following typ... | View trial NCT01037790 |
| Abramson Cancer Center | Trial sponsor | Mentioned in trial textTrial free-text mention | CCND1 | View trial NCT01037790 |
| Alliance for Clinical Trials in Oncology | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * • Histologically confirmed mantle cell lymphoma with cyclin D1 (BCL1) expression by immunohistochemical stains and/or evidence of CCND1 rearrangement or... | View trial NCT05976763 |
| Alliance for Clinical Trials in Oncology | Trial sponsor | Mentioned in trial textTrial free-text mention | CCND1 | View trial NCT02523014 |
| Alliance for Clinical Trials in Oncology | Trial sponsor | Mentioned in trial textTrial free-text mention | CCND1 | View trial NCT05976763 |
Showing 5 of 193 sourcing records.
Trial-cited literature (1,093)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4/6 Pathway. | Head & neck | 2026 | 0 |
| Exosomes from human umbilical cord mesenchymal stem cells promote the growth of human hair dermal papilla cells. | PloS one | 2025 | 8 |
| Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study. | JCO precision oncology | 2025 | 3 |
| miR-29b-3p Affects the Hypertrophy of Ligamentum Flavum in Lumbar Spinal Stenosis and its Mechanism. | Biochemical genetics | 2025 | 3 |
| Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). | Signal transduction and targeted therapy | 2025 | 2 |
Showing 5 of 1,093 papers.
Protein variant mentions (6)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.G870A | 1 | 2014 | PMID 24407191 |
| p.R80A | 1 | 2013 | PMID 24285483 |
| p.S1E | 1 | 2008 | PMID 19041748 |
| p.S2E | 1 | 2008 | PMID 19041748 |
| p.X109L | 1 | 2013 | PMID 23442309 |
Showing 5 of 6 variants.
Literature-extracted relations (190)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Adenosine | Chemical | negative_correlate |
Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1. | 2022 |
| TELMISARTAN | Chemical | negative_correlate |
Antihypertensive drug telmisartan suppresses the proliferation of gastric cancer cells in vitro and in vivo. | 2020 |
| TELMISARTAN | Chemical | negative_correlate |
Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro. | 2020 |
| Letrozole | Chemical | associate |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. | 2018 |
| TELMISARTAN | Chemical | negative_correlate |
Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. | 2017 |
Showing 5 of 190 relation assertions.
Organizations publishing (738)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 54 | 2002 to 2023 |
| The University of Texas System | Academic | 52 | 2001 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 49 | 2011 to 2023 |
| Harvard Medical School | Academic | 40 | 2002 to 2025 |
| Mayo Clinic | Hospital | 35 | 2005 to 2023 |
Showing 5 of 738 organizations.
Where CCND1 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
561 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.